Studies on the most effective of the commonly used bone-specific drugs, the antiresorptives zoledronic acid and denosumab, as well as up-to-date menopausal hormone therapy for early prevention refer to sound long-term safety data. However, depending on both the patient's characteristics and the properties of the respective regimens, the rates of side-effects, tolerability and persistence differ substantially. They are crucial limiting factors for actual efficacy in the clinical setting and thus determine the length and continuation of treatment.
Keywords: DENOSUMAB; EFFICACY; MENOPAUSAL HORMONE THERAPY; PERSISTENCE; SAFETY; ZOLEDRONIC ACID.